These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30388194)

  • 1. Blood Schizonticidal Activity and Safety of Tafenoquine When Administered as Chemoprophylaxis to Healthy, Nonimmune Participants Followed by Blood Stage Plasmodium falciparum Challenge: A Randomized, Double-blind, Placebo-controlled Phase 1b Study.
    McCarthy JS; Smith B; Reid M; Berman J; Marquart L; Dobbin C; West L; Read LT; Dow GS
    Clin Infect Dis; 2019 Jul; 69(3):480-486. PubMed ID: 30388194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.
    Hale BR; Owusu-Agyei S; Fryauff DJ; Koram KA; Adjuik M; Oduro AR; Prescott WR; Baird JK; Nkrumah F; Ritchie TL; Franke ED; Binka FN; Horton J; Hoffman SL
    Clin Infect Dis; 2003 Mar; 36(5):541-9. PubMed ID: 12594633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
    Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
    Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malaria chemoprophylaxis with tafenoquine: a randomised study.
    Lell B; Faucher JF; Missinou MA; Borrmann S; Dangelmaier O; Horton J; Kremsner PG
    Lancet; 2000 Jun; 355(9220):2041-5. PubMed ID: 10885356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries.
    Dow GS; Liu J; Lin G; Hetzell B; Thieling S; McCarthy WF; Tang D; Smith B
    Malar J; 2015 Nov; 14():473. PubMed ID: 26610844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
    Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ
    Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
    Barber BE; Abd-Rahman AN; Webster R; Potter AJ; Llewellyn S; Marquart L; Sahai N; Leelasena I; Birrell GW; Edstein MD; Shanks GD; Wesche D; Moehrle JJ; McCarthy JS
    Clin Infect Dis; 2023 Jun; 76(11):1919-1927. PubMed ID: 36795050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.
    Shanks GD; Oloo AJ; Aleman GM; Ohrt C; Klotz FW; Braitman D; Horton J; Brueckner R
    Clin Infect Dis; 2001 Dec; 33(12):1968-74. PubMed ID: 11700577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
    N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
    Walsh DS; Eamsila C; Sasiprapha T; Sangkharomya S; Khaewsathien P; Supakalin P; Tang DB; Jarasrumgsichol P; Cherdchu C; Edstein MD; Rieckmann KH; Brewer TG
    J Infect Dis; 2004 Oct; 190(8):1456-63. PubMed ID: 15378438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
    N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg).
    Dow G; Smith B
    Malar J; 2017 May; 16(1):209. PubMed ID: 28526056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
    van der Plas JL; Kuiper VP; Bagchus WM; Bödding M; Yalkinoglu Ö; Tappert A; Seitzinger A; Spangenberg T; Bezuidenhout D; Wilkins J; Oeuvray C; Dhingra SK; Thathy V; Fidock DA; Smidt LCA; Roozen GVT; Koopman JPR; Lamers OAC; Sijtsma J; van Schuijlenburg R; Wessels E; Meij P; Kamerling IMC; Roestenberg M; Khandelwal A
    Lancet Infect Dis; 2023 Oct; 23(10):1164-1174. PubMed ID: 37414066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.
    Murphy SC; Duke ER; Shipman KJ; Jensen RL; Fong Y; Ferguson S; Janes HE; Gillespie K; Seilie AM; Hanron AE; Rinn L; Fishbaugher M; VonGoedert T; Fritzen E; Kappe SH; Chang M; Sousa JC; Marcsisin SR; Chalon S; Duparc S; Kerr N; Möhrle JJ; Andenmatten N; Rueckle T; Kublin JG
    J Infect Dis; 2018 Feb; 217(5):693-702. PubMed ID: 29216395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
    Webster R; Mitchell H; Peters JM; Heunis J; O'Neill B; Gower J; Lynch S; Jennings H; Amante FH; Llewellyn S; Marquart L; Potter AJ; Birrell GW; Edstein MD; Shanks GD; McCarthy JS; Barber BE
    Clin Infect Dis; 2023 Feb; 76(3):506-512. PubMed ID: 35731843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval of Tafenoquine for Malaria Chemoprophylaxis.
    Berman JD
    Am J Trop Med Hyg; 2019 Jun; 100(6):1301-1304. PubMed ID: 30887947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.
    Chughlay MF; El Gaaloul M; Donini C; Campo B; Berghmans PJ; Lucardie A; Marx MW; Cherkaoui-Rbati MH; Langdon G; Angulo-Barturen I; Viera S; Rosanas-Urgell A; Van Geertruyden JP; Chalon S
    Am J Trop Med Hyg; 2021 Feb; 104(4):1348-1358. PubMed ID: 33556040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.
    Dow GS; McCarthy WF; Reid M; Smith B; Tang D; Shanks GD
    Malar J; 2014 Feb; 13():49. PubMed ID: 24502679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.
    Healy SA; Murphy SC; Hume JCC; Shelton L; Kuntz S; Van Voorhis WC; Moodie Z; Metch B; Wang R; Silver-Brace T; Fishbaugher M; Kennedy M; Finney OC; Chaturvedi R; Marcsisin SR; Hobbs CV; Warner-Lubin M; Talley AK; Wong-Madden S; Stuart K; Wald A; Kappe SH; Kublin JG; Duffy PE
    Clin Infect Dis; 2020 Sep; 71(6):1481-1490. PubMed ID: 31621832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.